Skip to main content
. Author manuscript; available in PMC: 2020 Sep 2.
Published in final edited form as: Invest New Drugs. 2017 Mar 10;35(5):627–633. doi: 10.1007/s10637-017-0444-1

Table 1.

Patients Demographics and Baseline Characteristics

Part 1
N=14
Part 2
N=32
All Patients
N=46
Age, years, mean (range) 50.6 (26, 72) 61.2 (36, 78) 58 (26, 78)
Sex, n (%)
  Female 13 (92.9) 27 (84.4) 40 (87)
  Male 1 (7.1) 5 (15.6) 6 (13)
Race, n (%)
  White 13 (92.9) 30 (93.8) 43 (93.5)
  Asian 1 (7.1) 1 (3.1) 2 (4.3)
  Black or African American 0 1 (3.1) 1 (2.2)
Ethnicity, n (%)
  Hispanic or Latino 2 (14.3) 1 (3.1) 3 (6.5)
Primary tumor type, n (%)
  Ovarian 8 (57.1) 20 (62.5) 28 (60.9)
  SCLC 1 (7.1) 12 (37.5) 13 (28.3))
  Cervical 5 (35.7) 0 5 (10.9)
Prior lines of therapy, mean (range)
  Ovarian 3.0 (2–4) 3.2 (1–4) 3.1 (1–4)
  SCLC 1.0 (1) 1.5 (1–3) 1.5 (1–3)
  Cervical 2.8 (1–4) N/A 2.8 (1–4)
ECOG stage, n (%)
  0 4 (28.6) 13 (40.6) 17 (37)
  1 10 (71.4) 19 (59.4) 29 (63)